Table 15.4.1.2
Number of SAEs through Day 28 by system organ class, preferred term, and severity
Safety analysis set

System Organ Class (SOC) Preferred Term (PT) Severity	Treatment Placebo (N=108) n_{AEs}	 n (%)		 Ilofotase Alfa (N=112) n_{AEs}	 n (%)		 Total (N=220) n_{AEs}	 n (%)	
Any SAE through Day 28	35	22	(20.4)	25	22	(19.6)	60	44	(20.0)
Mild	1	1	(0.9)	1	1	(0.9)	2	2	(0.9)
Moderate	10	9	(8.3)	9	7	(6.3)	19	16	(7.3)
Severe	24	16	(14.8)	15	15	(13.4)	39	31	(14.1)
Blood and lymphatic system disorders	0	0	(0.0)	1	1	(0.9)	1	1	(0.5)
Moderate	0	0	(0.0)	1	1	(0.9)	1	1	(0.5)
Anaemia	0	0	(0.0)	1	1	(0.9)	1	1	(0.5)
Moderate	0	0	(0.0)	1	1	(0.9)	1	1	(0.5)
Cardiac disorders	11	9	(8.3)	10	10	(8.9)	21	19	(8.6)
Mild	1	1	(0.9)	0	0	(0.0)	1	1	(0.5)
Moderate	2	2	(1.9)	0	0	(0.0)	2	2	(0.9)
Severe	8	7	(6.5)	10	10	(8.9)	18	17	(7.7)
Acute coronary syndrome	1	1	(0.9)	0	0	(0.0)	1	1	(0.5)
Severe	1	1	(0.9)	0	0	(0.0)	1	1	(0.5)
Arrhythmia	1	1	(0.9)	0	0	(0.0)	1	1	(0.5)
Severe	1	1	(0.9)	0	0	(0.0)	1	1	(0.5)
Atrial fibrillation	0	0	(0.0)	2	2	(1.8)	2	2	(0.9)
Severe	0	0	(0.0)	2	2	(1.8)	2	2	(0.9)
Atrial thrombosis	1	1	(0.9)	0	0	(0.0)	1	1	(0.5)
Mild	1	1	(0.9)	0	0	(0.0)	1	1	(0.5)
Atrioventricular block complete	2	2	(1.9)	2	2	(1.8)	4	4	(1.8)
Severe	2	2	(1.9)	2	2	(1.8)	4	4	(1.8)
Bradycardia	1	1	(0.9)	0	0	(0.0)	1	1	(0.5)
Severe	1	1	(0.9)	0	0	(0.0)	1	1	(0.5)
Cardiac arrest	0	0	(0.0)	1	1	(0.9)	1	1	(0.5)

SAEs through Day 28 are defined as all SAEs with a start day prior or equal to Day 28 (Day 28 as reported in EDC). For patients without Day 28 visit, study day 28 was used.
AEs documented as serious on the AE form are tabulated.
The number of patients at a SOC level is not necessarily the sum of those at the PT levels since a patient may report multiple AEs within a SOC level.
AEs coded by MedDRA V26.1.
n_{AEs} = Number of adverse events. n = Number of patients with adverse events.

Table 15.4.1.2
Number of SAEs through Day 28 by system organ class, preferred term, and severity
Safety analysis set

System Organ Class (SOC) Preferred Term (PT) Severity	Treatment Placebo (N=108) n_{AEs}	 n (%)		 Ilofotase Alfa (N=112) n_{AEs}	 n (%)		 Total (N=220) n_{AEs}	 n (%)	
Severe	0	0	(0.0)	1	1	(0.9)	1	1	(0.5)
Cardiac failure	1	1	(0.9)	0	0	(0.0)	1	1	(0.5)
Moderate	1	1	(0.9)	0	0	(0.0)	1	1	(0.5)
Cardiac tamponade	1	1	(0.9)	1	1	(0.9)	2	2	(0.9)
Severe	1	1	(0.9)	1	1	(0.9)	2	2	(0.9)
Cardiogenic shock	1	1	(0.9)	1	1	(0.9)	2	2	(0.9)
Severe	1	1	(0.9)	1	1	(0.9)	2	2	(0.9)
Dressler's syndrome	0	0	(0.0)	1	1	(0.9)	1	1	(0.5)
Severe	0	0	(0.0)	1	1	(0.9)	1	1	(0.5)
Myocardial infarction	1	1	(0.9)	0	0	(0.0)	1	1	(0.5)
Moderate	1	1	(0.9)	0	0	(0.0)	1	1	(0.5)
Pericardial effusion	0	0	(0.0)	2	2	(1.8)	2	2	(0.9)
Severe	0	0	(0.0)	2	2	(1.8)	2	2	(0.9)
Pulseless electrical activity	1	1	(0.9)	0	0	(0.0)	1	1	(0.5)
Severe	1	1	(0.9)	0	0	(0.0)	1	1	(0.5)
General disorders and administration site conditions	1	1	(0.9)	2	2	(1.8)	3	3	(1.4)
Moderate	0	0	(0.0)	2	2	(1.8)	2	2	(0.9)
Severe	1	1	(0.9)	0	0	(0.0)	1	1	(0.5)
Impaired healing	0	0	(0.0)	1	1	(0.9)	1	1	(0.5)
Moderate	0	0	(0.0)	1	1	(0.9)	1	1	(0.5)
Malaise	0	0	(0.0)	1	1	(0.9)	1	1	(0.5)
Moderate	0	0	(0.0)	1	1	(0.9)	1	1	(0.5)
Multiple organ dysfunction syndrome	1	1	(0.9)	0	0	(0.0)	1	1	(0.5)
Severe	1	1	(0.9)	0	0	(0.0)	1	1	(0.5)
Infections and infestations	11	11	(10.2)	1	1	(0.9)	12	12	(5.5)

SAEs through Day 28 are defined as all SAEs with a start day prior or equal to Day 28 (Day 28 as reported in EDC). For patients without Day 28 visit, study day 28 was used.
AEs documented as serious on the AE form are tabulated.
The number of patients at a SOC level is not necessarily the sum of those at the PT levels since a patient may report multiple AEs within a SOC level.
AEs coded by MedDRA V26.1.
n_{AEs} = Number of adverse events. n = Number of patients with adverse events.

Table 15.4.1.2
Number of SAEs through Day 28 by system organ class, preferred term, and severity
Safety analysis set

System Organ Class (SOC) Preferred Term (PT) Severity	Treatment Placebo (N=108) n_{AEs}	 n (%)		 Ilofotase Alfa (N=112) n_{AEs}	 n (%)		 Total (N=220) n_{AEs}	 n (%)	
Moderate	4	4	(3.7)	1	1	(0.9)	5	5	(2.3)
Severe	7	7	(6.5)	0	0	(0.0)	7	7	(3.2)
Cellulitis	1	1	(0.9)	0	0	(0.0)	1	1	(0.5)
Moderate	1	1	(0.9)	0	0	(0.0)	1	1	(0.5)
Enterococcal bacteraemia	1	1	(0.9)	0	0	(0.0)	1	1	(0.5)
Moderate	1	1	(0.9)	0	0	(0.0)	1	1	(0.5)
Erysipelas	1	1	(0.9)	0	0	(0.0)	1	1	(0.5)
Severe	1	1	(0.9)	0	0	(0.0)	1	1	(0.5)
Mediastinitis	1	1	(0.9)	0	0	(0.0)	1	1	(0.5)
Severe	1	1	(0.9)	0	0	(0.0)	1	1	(0.5)
Nosocomial infection	1	1	(0.9)	0	0	(0.0)	1	1	(0.5)
Severe	1	1	(0.9)	0	0	(0.0)	1	1	(0.5)
Pneumocystis jirovecii pneumonia	1	1	(0.9)	0	0	(0.0)	1	1	(0.5)
Severe	1	1	(0.9)	0	0	(0.0)	1	1	(0.5)
Pneumonia	1	1	(0.9)	1	1	(0.9)	2	2	(0.9)
Moderate	0	0	(0.0)	1	1	(0.9)	1	1	(0.5)
Severe	1	1	(0.9)	0	0	(0.0)	1	1	(0.5)
Upper respiratory tract infection	1	1	(0.9)	0	0	(0.0)	1	1	(0.5)
Severe	1	1	(0.9)	0	0	(0.0)	1	1	(0.5)
Urinary tract infection	2	2	(1.9)	0	0	(0.0)	2	2	(0.9)
Moderate	2	2	(1.9)	0	0	(0.0)	2	2	(0.9)
Urosepsis	1	1	(0.9)	0	0	(0.0)	1	1	(0.5)
Severe	1	1	(0.9)	0	0	(0.0)	1	1	(0.5)
Injury, poisoning and procedural complications	4	3	(2.8)	5	5	(4.5)	9	8	(3.6)
Mild	0	0	(0.0)	1	1	(0.9)	1	1	(0.5)
Moderate	1	1	(0.9)	1	1	(0.9)	2	2	(0.9)

SAEs through Day 28 are defined as all SAEs with a start day prior or equal to Day 28 (Day 28 as reported in EDC). For patients without Day 28 visit, study day 28 was used.
AEs documented as serious on the AE form are tabulated.
The number of patients at a SOC level is not necessarily the sum of those at the PT levels since a patient may report multiple AEs within a SOC level.
AEs coded by MedDRA V26.1.
n_{AEs} = Number of adverse events. n = Number of patients with adverse events.

Table 15.4.1.2
Number of SAEs through Day 28 by system organ class, preferred term, and severity
Safety analysis set

System Organ Class (SOC) Preferred Term (PT) Severity	Treatment Placebo (N=108) n_{AEs}	 n (%)		 Ilofotase Alfa (N=112) n_{AEs}	 n (%)		 Total (N=220) n_{AEs}	 n (%)	
Severe	3	2	(1.9)	3	3	(2.7)	6	5	(2.3)
Anastomotic haemorrhage	0	0	(0.0)	1	1	(0.9)	1	1	(0.5)
Severe	0	0	(0.0)	1	1	(0.9)	1	1	(0.5)
Post procedural discharge	0	0	(0.0)	1	1	(0.9)	1	1	(0.5)
Mild	0	0	(0.0)	1	1	(0.9)	1	1	(0.5)
Post procedural haemorrhage	1	1	(0.9)	1	1	(0.9)	2	2	(0.9)
Moderate	0	0	(0.0)	1	1	(0.9)	1	1	(0.5)
Severe	1	1	(0.9)	0	0	(0.0)	1	1	(0.5)
Postoperative delirium	1	1	(0.9)	0	0	(0.0)	1	1	(0.5)
Moderate	1	1	(0.9)	0	0	(0.0)	1	1	(0.5)
Postoperative respiratory failure	0	0	(0.0)	1	1	(0.9)	1	1	(0.5)
Severe	0	0	(0.0)	1	1	(0.9)	1	1	(0.5)
Postoperative thoracic procedure complication	1	1	(0.9)	1	1	(0.9)	2	2	(0.9)
Severe	1	1	(0.9)	1	1	(0.9)	2	2	(0.9)
Procedural haemorrhage	1	1	(0.9)	0	0	(0.0)	1	1	(0.5)
Severe	1	1	(0.9)	0	0	(0.0)	1	1	(0.5)
Metabolism and nutrition disorders	1	1	(0.9)	0	0	(0.0)	1	1	(0.5)
Severe	1	1	(0.9)	0	0	(0.0)	1	1	(0.5)
Lactic acidosis	1	1	(0.9)	0	0	(0.0)	1	1	(0.5)
Severe	1	1	(0.9)	0	0	(0.0)	1	1	(0.5)
Nervous system disorders	0	0	(0.0)	1	1	(0.9)	1	1	(0.5)
Moderate	0	0	(0.0)	1	1	(0.9)	1	1	(0.5)
Middle cerebral artery stroke	0	0	(0.0)	1	1	(0.9)	1	1	(0.5)
Moderate	0	0	(0.0)	1	1	(0.9)	1	1	(0.5)

SAEs through Day 28 are defined as all SAEs with a start day prior or equal to Day 28 (Day 28 as reported in EDC). For patients without Day 28 visit, study day 28 was used.
AEs documented as serious on the AE form are tabulated.
The number of patients at a SOC level is not necessarily the sum of those at the PT levels since a patient may report multiple AEs within a SOC level.
AEs coded by MedDRA V26.1.
n_{AEs} = Number of adverse events. n = Number of patients with adverse events.

Table 15.4.1.2
Number of SAEs through Day 28 by system organ class, preferred term, and severity
Safety analysis set

System Organ Class (SOC) Preferred Term (PT) Severity	Treatment Placebo (N=108) n_{AEs}	 n (%)		 Ilofotase Alfa (N=112) n_{AEs}	 n (%)		 Total (N=220) n_{AEs}	 n (%)	
Renal and urinary disorders	3	3	(2.8)	1	1	(0.9)	4	4	(1.8)
Moderate	2	2	(1.9)	1	1	(0.9)	3	3	(1.4)
Severe	1	1	(0.9)	0	0	(0.0)	1	1	(0.5)
Acute kidney injury	3	3	(2.8)	1	1	(0.9)	4	4	(1.8)
Moderate	2	2	(1.9)	1	1	(0.9)	3	3	(1.4)
Severe	1	1	(0.9)	0	0	(0.0)	1	1	(0.5)
Reproductive system and breast disorders	0	0	(0.0)	1	1	(0.9)	1	1	(0.5)
Moderate	0	0	(0.0)	1	1	(0.9)	1	1	(0.5)
Prostatitis	0	0	(0.0)	1	1	(0.9)	1	1	(0.5)
Moderate	0	0	(0.0)	1	1	(0.9)	1	1	(0.5)
Respiratory, thoracic and mediastinal disorders	4	4	(3.7)	1	1	(0.9)	5	5	(2.3)
Moderate	1	1	(0.9)	0	0	(0.0)	1	1	(0.5)
Severe	3	3	(2.8)	1	1	(0.9)	4	4	(1.8)
Dyspnoea	1	1	(0.9)	0	0	(0.0)	1	1	(0.5)
Severe	1	1	(0.9)	0	0	(0.0)	1	1	(0.5)
Epistaxis	1	1	(0.9)	0	0	(0.0)	1	1	(0.5)
Moderate	1	1	(0.9)	0	0	(0.0)	1	1	(0.5)
Pleural effusion	1	1	(0.9)	1	1	(0.9)	2	2	(0.9)
Severe	1	1	(0.9)	1	1	(0.9)	2	2	(0.9)
Pulmonary oedema	1	1	(0.9)	0	0	(0.0)	1	1	(0.5)
Severe	1	1	(0.9)	0	0	(0.0)	1	1	(0.5)
Vascular disorders	0	0	(0.0)	2	2	(1.8)	2	2	(0.9)
Moderate	0	0	(0.0)	1	1	(0.9)	1	1	(0.5)
Severe	0	0	(0.0)	1	1	(0.9)	1	1	(0.5)

SAEs through Day 28 are defined as all SAEs with a start day prior or equal to Day 28 (Day 28 as reported in EDC). For patients without Day 28 visit, study day 28 was used.
AEs documented as serious on the AE form are tabulated.
The number of patients at a SOC level is not necessarily the sum of those at the PT levels since a patient may report multiple AEs within a SOC level.
AEs coded by MedDRA V26.1.
n_{AEs} = Number of adverse events. n = Number of patients with adverse events.

Table 15.4.1.2
Number of SAEs through Day 28 by system organ class, preferred term, and severity
Safety analysis set

System Organ Class (SOC) Preferred Term (PT) Severity	Treatment Placebo (N=108) n_{AEs}	 n (%)		 Ilofotase Alfa (N=112) n_{AEs}	 n (%)		 Total (N=220) n_{AEs}	 n (%)	
Haemodynamic instability	0	0	(0.0)	1	1	(0.9)	1	1	(0.5)
Moderate	0	0	(0.0)	1	1	(0.9)	1	1	(0.5)
Thrombosis	0	0	(0.0)	1	1	(0.9)	1	1	(0.5)
Severe	0	0	(0.0)	1	1	(0.9)	1	1	(0.5)

SAEs through Day 28 are defined as all SAEs with a start day prior or equal to Day 28 (Day 28 as reported in EDC). For patients without Day 28 visit, study day 28 was used.
AEs documented as serious on the AE form are tabulated.
The number of patients at a SOC level is not necessarily the sum of those at the PT levels since a patient may report multiple AEs within a SOC level.
AEs coded by MedDRA V26.1.
n_{AEs} = Number of adverse events. n = Number of patients with adverse events.